Document is current
Any future updates will be listed below
-
Authors
Othus, Megan https://orcid.org/0000-0001-8176-6371
Garcia-Manero, Guillermo https://orcid.org/0000-0002-3631-2482
Appelbaum, Frederick R. https://orcid.org/0000-0002-1839-5069
Erba, Harry P.
Dietrich, Eliana https://orcid.org/0009-0000-8836-0374
Raychaudhuri, Suravi https://orcid.org/0000-0001-6516-5293
Appelbaum, Jacob https://orcid.org/0000-0002-4362-7773
Estey, Elihu
Percival, Mary-Elizabeth
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA180819)
- License Information
-
More Information
Article History
Received: 1 October 2024
Revised: 2 October 2024
Accepted: 30 December 2024
First Online: 27 January 2025
Competing interests
: MO: consulting fees from Merck and Biosights; Data Safety Monitoring Board Member for BMS, Glycomimetics, Grifols. MP: clinical trial research funding (to institution) from Abbvie, Ascentage, Astex, Biosight, BMS, Immunogen, Pfizer.
